2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

Previous Symposia

2015 Featured Talks » Bringing Btk inhibition forward



Bringing Btk inhibition forward

Danelle James, MD, MAS
Pharmacyclics


Part One


Part Two




Danelle James, MD, MAS
Head of Oncology
Pharmacyclics


Danelle James is Head of Oncology at Pharmacyclics where she leads clinical development efforts for CLL/SLL, Graft vs Host Disease, and Solid tumors. Prior to joining Pharmacyclics in 2011, Dr. James was a faculty member in the Department of Medicine, Division of Hematology and Oncology at University of California San Diego. Her research focus there for ten years, was the study of the Chronic Lymphocytic Leukemia (CLL) and the tumor microenvironment and the clinical-translational development of agents that can be used to target these interactions. Danelle worked closely under the mentorship of Thomas Kipps and as a member CLL Research Consortium (CRC), she co-coordinated the clinical trials program evaluating the combination of novel agents for the treatment of CLL. Danelle started her career in industry more than 18 years ago at Biogen in Cambridge Massachusetts where she worked in the Department of Immunology and Inflammation.

Dr. James completed Internal Medicine residency and Hematology/Oncology fellowship at UCSD, is Board Certified in Internal Medicine and in Hematology. She obtained formal education in clinical research methodologies and a Masters degree in Advanced Studies of Clinical Research from UCSD.